Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1988 1
1991 1
1994 4
1995 6
1996 3
1997 7
1998 5
1999 3
2000 3
2001 7
2002 3
2003 3
2004 8
2005 6
2006 14
2007 19
2008 16
2009 19
2010 24
2011 20
2012 22
2013 18
2014 28
2015 24
2016 15
2017 11
2018 20
2019 17
2020 17
2021 31
2022 26
2023 15
2024 11
2025 8
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: westhovens r. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Ann Rheum Dis. 2023. PMID: 36357155 Free article.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: westhovens r. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. Ann Rheum Dis. 2020. PMID: 31969328 Free article.
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.
Parodis I, Girard-Guyonvarc'h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, Fligelstone K, Kocher A, Larosa M, Lau M, Mitropoulos A, Ndosi M, Poole JL, Redmond A, Ritschl V, Alexanderson H, Sjöberg Y, von Perner G, Uhlig T, Varju C, Vriezekolk JE, Welin E, Westhovens R, Stamm TA, Boström C. Parodis I, et al. Among authors: westhovens r. Ann Rheum Dis. 2024 May 15;83(6):720-729. doi: 10.1136/ard-2023-224416. Ann Rheum Dis. 2024. PMID: 37433575 Free article.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. Smolen JS, et al. Among authors: westhovens r. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Free article. Review.
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group. van Laar JM, et al. Among authors: westhovens r. JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368. JAMA. 2014. PMID: 25058083 Free article. Clinical Trial.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Nash P, et al. Among authors: westhovens r. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dörner T, Fleischmann R, McInnes I, Primdahl J, Sattar N, Tanaka Y, Trauner M, Winthrop K, de Wit M, Askling J, Baraliakos X, Boehncke WH, Emery P, Gossec L, Isaacs JD, Krauth M, Lee EB, Maksymowych W, Pope J, Scholte-Voshaar M, Schreiber K, Schreiber S, Stamm T, Taylor PC, Takeuchi T, Tam LS, Van den Bosch F, Westhovens R, Zeitlinger M, Smolen JS. Nash P, et al. Among authors: westhovens r. Ann Rheum Dis. 2025 May;84(5):664-679. doi: 10.1016/j.ard.2025.01.032. Epub 2025 Mar 3. Ann Rheum Dis. 2025. PMID: 40037995 Free article.
Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis.
Tanaka Y, Westhovens R, Sun H, Van der Donckt C, Zhong Y, Kaise T. Tanaka Y, et al. Among authors: westhovens r. Rheumatol Ther. 2025 Jun;12(3):453-468. doi: 10.1007/s40744-025-00757-7. Epub 2025 Apr 10. Rheumatol Ther. 2025. PMID: 40208566 Free PMC article. Review.
Filgotinib in rheumatoid arthritis.
Westhovens R. Westhovens R. Expert Rev Clin Immunol. 2023 Feb;19(2):135-144. doi: 10.1080/1744666X.2023.2149495. Epub 2022 Nov 21. Expert Rev Clin Immunol. 2023. PMID: 36396615 Review.
Foreword from the judges.
Tan AL, Westhovens R, Ndosi M. Tan AL, et al. Among authors: westhovens r. Rheumatol Adv Pract. 2021 Nov 5;5(Suppl 2):iia. doi: 10.1093/rap/rkab080. eCollection 2021 Nov. Rheumatol Adv Pract. 2021. PMID: 34755029 Free PMC article. No abstract available.
367 results